Simple blood tests detect autoimmune kidney disease, help predict prognosis

September 6, 2012

Simple blood tests could help physicians decide which patients with a particular autoimmune kidney disease can forgo potentially toxic medications and which need to be treated, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Idiopathic membranous nephropathy is an autoimmune that leads to in at least half of patients if left untreated. is effective, but toxic. "It is unclear who should be treated, when treatment should be started, and how long treatment should be continued. We need better tools to aid decision-making," said Julia Hofstra, MD, PhD (Radboud University Nijmegen Medical Center, in The Netherlands).

Researchers have recently identified antibodies—called antiPLA2R —that form and damage the kidneys when the disease develops. Clinicians do not have a standard technique for measuring these autoantibodies nor do they know whether autoantibody levels provide any information about the severity of patients' disease.

Hofstra, in collaboration with Hanna Debiec, PhD (Institut National de la Santé et de la Recherche Médicale, in France), Paul Brenchley, PhD (University of Manchester, in the United Kingdom), and others compared two different blood tests (called IIFT and ELISA) to measure antiPLA2R autoantibodies in 117 patients with idiopathic membranous nephropathy.

Among the major findings:

  • 74% of patients tested positive for antiPLA2R antibodies by IIFT and 72% tested positive by ELISA.
  • Concordance between both tests was excellent, with 94% agreement.
  • Antibody levels significantly correlated with the severity of patients' disease.
  • Spontaneous remissions occurred much less frequently among patients with high antibody levels (38% versus 4% in the lowest and highest groups, respectively).
The findings reveal high agreement between IIFT and ELISA measurements of antiPLA2R antibody levels and highlight the important role of these antibodies in idiopathic membranous nephropathy, given the relationships between antiPLA2R levels, disease severity, and remission rates.

"The data provide hope that in the near future, antiPLA2R antibodies can be detected with a simple assay and measuring the may improve optimal treatment in patients with idiopathic membranous nephropathy," said Dr. Hofstra.

Explore further: Blood markers reveal severity of common kidney disease

More information: The article, entitled "Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy," will appear online on September 6, 2012, doi: 10.1681/ASN.2012030242

Related Stories

Blood markers reveal severity of common kidney disease

August 16, 2012
Increasing blood levels of particular proteins may act as warning signs for patients with one of the most common diseases of the kidney, according to a study appearing in an upcoming issue of the Journal of the American Society ...

Researchers develop blood test to detect membranous nephropathy

December 1, 2011
Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages. ...

Immune drug helps patients with serious kidney disorder

July 19, 2012
A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue ...

Why some kidney disease patients can't repair blood vessels

October 27, 2011
In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). Inhibiting ...

Recommended for you

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.